Bayer announces that Asklepios BioPharmaceutical, an independent Bayer subsidiary, has appointed Mansuo Shannon as the company's Chief Scientific Officer (CSO).

Mansuo Shannon joins AskBio from Prevail Therapeutics, a 100%-owned subsidiary of Eli Lilly, where she also held the position of CSO.

Reporting to CEO Gustavo Pesquin, Mansuo Shannon will be a member of AskBio's management team, leading the R&D organization.

Co-founder and former Chief Scientific Officer R. Jude Samulski remains a member of AskBio's Board of Directors.

' As a seasoned pharmaceutical and biotech executive who has worked on an impressive range of therapeutic modalities, his experience will be invaluable as our company continues to advance as a leader in gene therapy,' said Gustavo Pesquin.

I am confident that Mansuo's extensive experience in neurodevelopmental and neurodegenerative diseases, in particular, will bring us closer to our strategic vision of creating a new reality for people suffering from diseases for which there is as yet no effective treatment.

Copyright (c) 2024 CercleFinance.com. All rights reserved.